MVA-member Alligator Bioscience and Orion Corporation initiate second immuno-oncology program

Jan 17, 2023

MVA-member company Alligator Bioscience has recently announced an expansion to its research collaboration and license agreement with Orion Corporation, to discover and develop together new bispecific antibody cancer therapeutics.

The collaboration has been expanded to add the development of a second bispecific antibody using Alligator’s bispecific RUBY platform, where Alligator will provide validated monospecific binders for one target and Orion will do the same for the other target.

”We are excited to start another joint project with Alligator Bioscience and continue our development of new immuno-oncology treatments, which has started very well,” said Outi Vaarala, Senior Vice President, R&D, of Orion Corporation.

“Our collaboration with Orion is progressing extremely well, with both companies making meaningful contributions to the first program and complementing each other’s scientific expertise,” says Søren Bregenholt, CEO of Alligator Bioscience. “The initiation of this second project is a testament to the strength of Alligator’s technology platform, including our bispecific RUBY format.”

Read full article in Nordic Life Science Days

Most recent news